SCHEMBL4827673

SCHEMBL4827673

Fc1cnc2[nH]cc(-c3oncc3-c3cccc(F)c3F)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT1 P54687 1/20 0.42
GSK3B P49841 6/20 0.41
GSK3A P49840 5/20 0.41
IRAK4 Q9NWZ3 4/20 0.41
SRC P12931 4/20 0.41
FLT3 P36888 4/20 0.41
MAP4K4 O95819 3/20 0.41
CLK4 Q9HAZ1 3/20 0.41
AXL P30530 3/20 0.41
ROCK2 O75116 3/20 0.41
CDK1 P06493 3/20 0.41
ROCK1 Q13464 3/20 0.41
DYRK3 O43781 2/20 0.41
PRKD3 O94806 2/20 0.41
ABL1 P00519 2/20 0.41
EGFR P00533 2/20 0.41
NTRK1 P04629 2/20 0.41
LCK P06239 2/20 0.41
FYN P06241 2/20 0.41
CSF1R P07333 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4824451 0.88 BCAT1 (0.41) BCAT1GSK3BGSK3AIRAK4SRC
SCHEMBL4831549 0.88 CDK2 (0.50) BCAT1GSK3BGSK3AIRAK4SRC
SCHEMBL4872228 0.88 JAK2 (0.50) BCAT1GSK3BGSK3AIRAK4SRC
SCHEMBL4831134 0.88 DYRK1A (0.42) BCAT1GSK3BGSK3AIRAK4SRC
SCHEMBL4829590 0.87 CDC7 (0.51) BCAT1GSK3BGSK3AIRAK4FLT3
SCHEMBL4829375 0.86 DYRK1A (0.42) BCAT1GSK3BGSK3AIRAK4SRC
SCHEMBL4831294 0.86 AXL (0.56) GSK3BGSK3AIRAK4SRCFLT3
SCHEMBL4825344 0.85 AXL (0.40) BCAT1GSK3BGSK3AIRAK4SRC
SCHEMBL4829477 0.85 CDK2 (0.43) BCAT1GSK3BGSK3AIRAK4SRC
SCHEMBL4823378 0.85 BCAT1 (0.39) BCAT1GSK3BGSK3AIRAK4SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
US-20050137201-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137201-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K6 BCAT1 1341/4885GSK3B 334/4885GSK3A 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.